Recombinant humanized anti-PD-1 monoclonal antibody injection

DRUG5 trials

Conditions

Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin LymphomaCancer of Unknown PrimaryCervical CancerEndometrial Cancer

Phase 1

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

NCT03657381

Shandong New Time Pharmaceutical Co., LTDAdvanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

Start: 2019-03-01End: 2022-10-08Target: 75Updated: 2020-10-22

Phase 2

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

NCT04848597

Fudan UniversityCancer of Unknown Primary

Start: 2021-05-13End: 2023-05-03Target: 48Updated: 2022-04-20

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

RecruitingNCT06123884

Bio-Thera SolutionsCervical Cancer

Start: 2023-12-13End: 2027-01-31Target: 526Updated: 2025-02-10

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

CompletedNCT06226350

Shandong New Time Pharmaceutical Co., LTDCervical Cancer

Start: 2021-03-04End: 2024-01-03Updated: 2024-01-26

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

TerminatedNCT06321068

Bio-Thera SolutionsEndometrial Cancer

Start: 2024-04-09End: 2025-08-07Updated: 2025-08-14

Related Papers

Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer.

Journal of Clinical Oncology2025-05-28